Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Gender and racial disparities in mortality persist, but the gap appears to have closed when it comes to getting the latest HIV treatment.
HIV treatment has come a long way, but there’s still room for innovation.
Five years of follow-up data show that starting antiretroviral therapy with a higher CD4 count has long-lasting benefits.
The study findings underscore the importance of starting antiretroviral therapy as soon as possible.
Over half of people with HIV and 17% of those newly diagnosed are 50 and older.
Many women could benefit from pre-exposure prophylaxis to prevent HIV.
New HIV treatment guidelines boost TAF and dolutegravir but warn about Trogarzo and advise against Cabenuva for pregnant people.
A high-quality trial should improve access to dolutegravir for children worldwide.
The updates include new information on optimizing therapy, dealing with virological failure and managing opportunistic infections.
New guidelines from the Department of Health and Human Services went into effect immediately.
PrEPception, breast feeding and HIV trial participation are front and center in updated federal guidelines.
HIVMA updated its 2013 guidance on providing evidence-based primary care to people with HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.